Tue. 12 Mar 2024, 6:24am ET
Benzinga
Biotech, News, Health Care, General
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration. It is being developed as a potential therapy for prevention and treatment of hospital acquired infection (REVTx-100 program) and as a potential treatment for acute and chronic organ disease including prevention of acute kidney injury (REVTx-300 program), myocarditis, and chronic kidney disease (CKD).